CEBPA and acute myeloid leukemia: Mutations in genes encoding Wilms tumor 1 (WT1), nucleophosmin (NPM1), FMS-like tyrosine kinase-3 (FLT3), and CCAAT/enhancer-binding protein alpha (CEBPA) affect the pathogenesis of AML [3].